Across TCGA pan-cancer cohorts, RGS10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RGS10 data layer compared with 21 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RGS10 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RGS10 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.
LUAD, HNSC, and PDAC are the cancer types where RGS10 mass-spec protein most reproducibly stratifies survival.